Aptose Biosciences slumps on stock offering
16/12/2019 21:49
** U.S.-listed shares of Canadian drug developer Aptose
Biosciences Inc APTO.O down 6.3% at $4.2 after market
** Launches stock offering; co did not indicate the size
** Aptose APS.TO intends a portion of net proceeds from
the offering on clinical trials for its drugs
** Piper Jaffray is the sole active book-running manager and
Canaccord Genuity is acting as passive book-running manager
** Underwriters have option to buy additional 15% of
offering
** Up to Monday's close, stock has more than doubled in
value this year
(Reporting by Bharath Manjesh in Bengaluru)
((Bharath.ManjeshR@thomsonreuters.com; outside U.S. +91 80
6749 8400;))
Recent news on Aptose Biosciences
See all newsBrief: Aptose Biosciences Says Closing Of Arrangement With Hanmi Pharmaceutical Further Delayed
Brief: Aptose Reports First Quarter 2026 Results
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan Of Arrangement
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Aptose Biosciences Shareholders Vote “For” Proposed Plan Of Arrangement With Hanmi Pharmaceutical
Brief: Aptose Biosciences Announces Amendment To Arrangement Agreement And Details Of Shareholders Meeting